CVHealthcare · Medical Devices

CV Stock Forecast: CapsoVision, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026

$6.62

+1.22% on the day

The 2 Wall Street analysts covering CapsoVision, Inc. hold a median 12-month price target of $9.5 — +43.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$348.0M

Ticker Nerd rank

20 / 100

Median analyst target

$9.50

Analysts covering

Revenue$3.6M+9.9% y/y

Operating income−$7.6M

Net income−$7.5M

Free cash flow−$8.4M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

+4.7%

+4.1%

YTD

−38.1%

+43.9%

From 52W high

−54.1%

From 52W low

+48.4%

$14

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

CV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CapsoVision, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026

20 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance

Momentum

Size

Accruals

Revisions

Value

Volatility

Quality

Growth

Issuance (62): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts

2 Buy0 Hold0 Sell

Low $9.00Median $9.50High $10.00

The green dot is the last close — the median target sits +43.5% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
27 Mar 2026	Benchmark	Maintains	Speculative Buy	$14 → $10
31 Dec 2025	Benchmark	Maintains	Speculative Buy	—
28 July 2025	Benchmark	Initiates	Speculative Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CV appears on the weeks it earns a place.

Performance

CV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, CapsoVision, Inc. returned +43.9% against +16.2% for the S&P 500, dividends included.

CV vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

CapsoVision, Inc. (CV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −6.4×
Price / sales: 25.4×
Price / book: 25.2×
EV / EBITDA: −10.8×

Growth & margins

Revenue growth (YoY): 9.9%
Earnings growth (YoY): —
Gross margin: 51.4%
Operating margin: −208.1%
Net margin: −214.7%

Returns & dividend

Return on equity: −335.1%
Return on assets: −132.5%
Dividend yield: 0.0%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CapsoVision, Inc. (CV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

CapsoVision, Inc. has a market value of $348.0M and an enterprise value of $318.9M.
Revenue in the twelve months to 30 June 2026: $13.9M. The latest quarter grew 9.9% year on year.
Net income over the same four quarters: −$29.8M, a −214.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$27.9M.
Shares outstanding: 50.0M.
Trailing P/E: −6.4×; forward P/E: −15.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CapsoVision, Inc. employs 99 people — $140K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

CV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
CVCapsoVision, Inc.	$348.0M	20
OFIXOrthofix Medical, Inc.	$356.4M	71
VMDViemed Healthcare, Inc.	$357.7M	94
SIShoulder Innovations, Inc.	$372.5M	25
CLPTClearpoint Neuro, Inc.	$312.1M	20
CATXPerspective Therapeutics, Inc.	$308.7M	36
RCELAVITA Medical, Inc.	$412.3M	73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CapsoVision, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CV news & analysis

CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®

GlobeNewsWire · 28 Sept 2026positive

CapsoVision announced that the FDA has cleared its AI Highlights feature, an AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus system.

Why it matters — This FDA clearance for AI Highlights extends the capability of CapsoCam Plus, potentially enhancing the product's clinical utility for CV watchers.

CapsoVision to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

CapsoVision, Inc. announced that its President and CEO Johnny Wang, Senior Vice President of Finance David Garcia, and Senior Vice President of Global Sales Doug Atkinson plan to participate in upcoming investor conferences, including H.C. Wainwright conferences.

Why it matters — The company's leadership team will present at investor conferences, giving CapsoVision watchers opportunities to hear directly about the company's capsule endoscopy business.

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Seeking Alpha published the transcript of CapsoVision, Inc.'s (CV) Q2 2026 earnings call. The item announces the availability of the transcript covering the company's quarterly earnings discussion, though no figures or details from the call are provided in this excerpt.

Why it matters — A CV watcher would care because the earnings call transcript is the primary source of management commentary and quarterly results for the company.

CapsoVision Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

CapsoVision reported second-quarter revenue growth driven by increased sales of its CapsoCam Plus capsule endoscopy system. The company also advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.

Why it matters — The revenue growth and progress on AI software and expanded gastrointestinal applications signal continued execution on CapsoVision's core product strategy and pipeline.

CapsoVision Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 13 Aug 2026neutral

CapsoVision, Inc. reported its second quarter 2026 financial results and provided a business update for the period ended June 30, 2026. The company, a commercial-stage developer of advanced imaging and AI-enabled capsule endoscopy solutions, made the announcement on August 13, 2026.

Why it matters — A CV watcher would care because quarterly financial results and the accompanying business update offer the latest picture of CapsoVision's operational and commercial performance.

FAQ

Frequently asked questions about CV stock

What is the CV stock price forecast for 2026-2027?

The 2 Wall Street analysts covering CapsoVision, Inc. have a median 12-month price target of $9.5, with estimates ranging from $9 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CV stock a buy right now?

Of the 2 analysts covering CapsoVision, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CapsoVision, Inc. 20 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CV?

As at 8 Oct 2026, CapsoVision, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (62 of 100).

Will CV stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +43.5% from the last close, and Ticker Nerd's factor model ranks CapsoVision, Inc. 20 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CV stock forecast for 2030?

No analyst covering CapsoVision, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $10 over the next 12 months.

How has CV stock performed over the past year?

CapsoVision, Inc. returned +43.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CapsoVision, Inc. do?

CapsoVision, Inc. is a commercial-stage medical technology company that develops, manufactures, and markets capsule endoscopy systems for gastrointestinal imaging.

What is the latest news on CV?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus®". CapsoVision announced that the FDA has cleared its AI Highlights feature, an AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus system.

Company

About CapsoVision, Inc.

CapsoVision, Inc. is a commercial-stage medical technology company that develops, manufactures, and markets capsule endoscopy systems for gastrointestinal imaging. The company’s products are designed to help clinicians visualize the GI tract for diagnostic and screening purposes, with a focus on detecting abnormalities such as bleeding, inflammation, and polyps. Its portfolio includes the CapsoCam Plus capsule endoscopy system for small-bowel visualization, along with cloud-based and direct-view software tools that support image retrieval and review. CapsoVision also offers solutions for colon imaging and related GI applications, combining advanced imaging with AI-enabled workflows to improve clinical efficiency. Based in Saratoga, California, CapsoVision serves hospitals, gastroenterology practices, and other medical providers seeking non-invasive tools for internal GI diagnostics.

CEO Mr. Kang-Huai Wang · 99 employees · United States · https://capsovision.com